ORBi: Detailled Reference

Article (Scientific journals)

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres, A.; Bonanni, P.; Hryniewicz, W. et al.

2014 • In European Journal of Clinical Microbiology and Infectious Diseases

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/172536

DOI
10.1007/s10096-014-2208-6

PubMed
25149825

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

art%3A10.1007%2Fs10096-014-2208-6.pdf

Publisher postprint (1.16 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Individuals <2 years and >/=50 years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune responses. The 7-valent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of vaccine-type pneumococcal diseases in children, including invasive disease and pneumonia and acute otitis media. There have also been significant declines in antimicrobial resistance in 7-valent vaccine serotypes and carriage of S. pneumoniae in the post-PCV7 era. Two to three years after the introduction of PCV13, there is emerging, global evidence of a reduced burden of pneumococcal diseases in children, including declines in IPD (UK and Germany) and nasopharyngeal carriage of PCV13 serotypes (Portugal and France). The functional immunogenicity of PCV13 in individuals >/=50 years of age has been demonstrated in clinical trials in comparison with the 23-valent pneumococcal polysaccharide vaccine and for children and adults 6 to 49 years of age. Between 2011 and 2013, PCV13 received market authorisation by the European Medicines Agency (EMA) for these additional age groups and is now available in Europe for the prevention of pneumococcal disease in all age groups.

Disciplines :

Immunology & infectious disease

Author, co-author :

Torres, A.

Bonanni, P.

Hryniewicz, W.

Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén.

Reinert, R. R.

Welte, T.

Language :

English

Title :

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Publication date :

2014

Journal title :

European Journal of Clinical Microbiology and Infectious Diseases

ISSN :

0934-9723

eISSN :

1435-4373

Publisher :

Springer, Germany

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 03 October 2014

Statistics

Number of views

76 (3 by ULiège)

Number of downloads

264 (1 by ULiège)

More statistics

Scopus citations^®

55

Scopus citations^®
without self-citations

52

OpenCitations

38

Bibliography

Butler JC, Schuchat A (1999) Epidemiology of pneumococcal infections in the elderly. Drugs Aging 15(Suppl 1):11–19
Torné AN, Dias JG, Quinten C, Hruba F, Busana MC, Lopalco PL, Gauci AJ, Pastore-Celentano L; ECDC country experts for pneumococcal disease (2014) European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 32:3644–3650
Rueda AM, Serpa JA, Matloobi M, Mushtaq M, Musher DM (2010) The spectrum of invasive pneumococcal disease at an adult tertiary care hospital in the early 21st century. Medicine (Baltimore) 89:331–336
Welte T (2012) How can we reduce the mortality of invasive pneumococcal disease? Eur Respir Rev 21:6–7
O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T; Hib and Pneumococcal Global Burden of Disease Study Team (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893–902
Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, Schouls LM, Sanders EA, van der Ende A (2009) Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 27:2394–2401
Torres A, Rodríguez-Créixems M, Grau I, Molinos L, Llinares P, De la Cruz JL, Rajas O, Alfageme I, Salavert M, Fenoll A, Liñares J, Cifuentes I (2013) Underlying clinical conditions and invasive pneumococcal disease (IPD) in adults in Spain (ODIN study, 2010–2012). Abstract 5051. European Respiratory Society (ERS) Annual Congress 2013, Barcelona, Spain, 7–11 September 2013. Available online at: http://www.ers-education.org/events/annual-congress.aspx?idParent=125517. Accessed 12 August 2014
van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E (2012) The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 65:17–24
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2003) Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med 348:1737–1746
Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Hadler JL, Farley MM, Anderson BJ, Schaffner W (2006) Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295:1668–1674
Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14:e197–e209
Rose MA, Christopoulou D, Myint TT, de Schutter I (2014) The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract 68:8–19
Nuorti JP (2000) Epidemiology of invasive pneumococcal disease in adults: implications for prevention. National Public Health Institute, Helsinki, Finland. Available online at: http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/nuorti/epidemio.pdf. Accessed 12 August 2014
Advisory Committee on Immunization Practices (2009) Recommended adult immunization schedule: United States, 2009. Ann Intern Med 150:40–44
Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, Masson P, De Keyser F (2010) Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 49:1815–1827
Gil-Prieto R, García-García L, Alvaro-Meca A, Méndez C, García A, de Miguel AG (2011) The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003–2007). Vaccine 29:412–416
Welte T, Torres A, Nathwani D (2012) Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67:71–79
Torres A, Peetermans WE, Viegi G, Blasi F (2013) Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68:1057–1065
Wright AE, Morgan WP, Colebrook L, Dodgson RW (1914) Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved by it. Lancet 183:1–10
Reinert RR, Paradiso P, Fritzell B (2010) Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev Vaccines 9:229–236
Centers for Disease Control and Prevention (CDC) (2013) Progress in introduction of pneumococcal conjugate vaccine—worldwide, 2000–2012. MMWR Morb Mortal Wkly Rep 62:308–311
GlaxoSmithKline Biologicals s.a. (2014) Synoflorix: summary of product characteristics. European Medicines Agency (EMA). Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000973/WC500054346.pdf. Accessed 12 August 2014
electronic Medicines Compendium (eMC) (2014) Prevenar 13 suspension for injection. eMC. Available online at: http://www.medicines.org.uk/emc/medicine/22689/SPC/Prevenar+13+suspension+for+injection/. Accessed 12 August 2014
Blanchard-Rohner G, Pollard AJ (2011) Long-term protection after immunization with protein–polysaccharide conjugate vaccines in infancy. Expert Rev Vaccines 10:673–684
Coutinho A, Möller G (1973) B cell mitogenic properties of thymus-independent antigens. Nat New Biol 245:12–14
Barrett DJ (1985) Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. Adv Pediatr 32:139–158
Barrett DJ, Ayoub EM (1986) IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin Exp Immunol 63:127–134
Toellner KM, Jenkinson WE, Taylor DR, Khan M, Sze DM, Sansom DM, Vinuesa CG, MacLennan IC (2002) Low-level hypermutation in T cell-independent germinal centers compared with high mutation rates associated with T cell-dependent germinal centers. J Exp Med 195:383–389
Taillardet M, Haffar G, Mondière P, Asensio MJ, Gheit H, Burdin N, Defrance T, Genestier L (2009) The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells. Blood 114:4432–4440
Obukhanych TV, Nussenzweig MC (2006) T-independent type II immune responses generate memory B cells. J Exp Med 203:305–310
Martin F, Oliver AM, Kearney JF (2001) Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 14:617–629
Birjandi SZ, Ippolito JA, Ramadorai AK, Witte PL (2011) Alterations in marginal zone macrophages and marginal zone B cells in old mice. J Immunol 186:3441–3451
Tortola L, Yadava K, Bachmann MF, Müller C, Kisielow J, Kopf M (2010) IL-21 induces death of marginal zone B cells during chronic inflammation. Blood 116:5200–5207
Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, Berner R, Peters A, Boehm T, Plebani A, Quinti I, Carsetti R (2003) Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 197:939–945
Kruschinski C, Zidan M, Debertin AS, von Hörsten S, Pabst R (2004) Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. Hum Pathol 35:113–121
Brodeur PH, Wortis HH (1980) Regulation of thymus-independent responses: unresponsiveness to a second challenge of TNP-Ficoll is mediated by hapten-specific antibodies. J Immunol 125:1499–1505
Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines. Nat Rev Immunol 9:213–220
Brynjolfsson SF, Henneken M, Bjarnarson SP, Mori E, Del Giudice G, Jonsdottir I (2012) Hyporesponsiveness following booster immunization with bacterial polysaccharides is caused by apoptosis of memory B cells. J Infect Dis 205:422–430
Kanswal S, Katsenelson N, Allman W, Uslu K, Blake MS, Akkoyunlu M (2011) Suppressive effect of bacterial polysaccharides on BAFF system is responsible for their poor immunogenicity. J Immunol 186:2430–2443
Wu ZQ, Vos Q, Shen Y, Lees A, Wilson SR, Briles DE, Gause WC, Mond JJ, Snapper CM (1999) In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions. J Immunol 163:659–667
MacLennan IC (1994) Germinal centers. Annu Rev Immunol 12:117–139
Avci FY, Li X, Tsuji M, Kasper DL (2011) A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 17:1602–1609
Centers for Disease Control and Prevention (CDC) (2008) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction—eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 57:144–148
Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, Fielding J, Giele C, Gilmour R, Holland R, Kampen R; Enhanced Invasive Pneumococcal Disease Surveillance Working Group, Brown M, Gilbert L, Hogg G, Murphy D; Pneumococcal Working Party of the Communicable Diseases Network Australia (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell Q Rep 32:18–30
Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D (2005) Progress in the prevention of pneumococcal infection. CMAJ 173:1149–1151
Dubos F, Marechal I, Husson MO, Courouble C, Aurel M, Martinot A; Hospital Network for Evaluating the Management of Common Childhood Diseases (2007) Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch Dis Child 92:1009–1012
Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A (2009) Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27:4136–4141
Vestrheim DF, Løvoll O, Aaberge IS, Caugant DA, Høiby EA, Bakke H, Bergsaker MR (2008) Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26:3277–3281
Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Pérez-Yarza EG (2009) Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur J Clin Microbiol Infect Dis 28:731–738
Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR (2007) Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369:1179–1186
Patrzałek M, Albrecht P, Sobczynski M (2010) Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 29:787–792
Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, Barth RD, Nuorti JP, Griffin MR (2007) Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119:707–715
Zhou F, Shefer A, Kong Y, Nuorti JP (2008) Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics 121:253–260
Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance of the Emerging Infections Program Network (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354:1455–1463
O’Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, Whitney CG, Santosham M (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196:1211–1220
Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA (2008) Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr Infect Dis J 27:519–525
Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL (2013) Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32:133–145
Barricarte A, Castilla J, Gil-Setas A, Torroba L, Navarro-Alonso JA, Irisarri F, Arriazu M (2007) Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case–control study. Clin Infect Dis 44:1436–1441
Bekri H, Cohen R, Varon E, Madhi F, Gire R, Guillot F, Delacourt C (2007) Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pediatr 14:239–243
Public Health England (2013) Current Epidemiology of Invasive Pneumococcal Disease (IPD). Public Health England. Available online at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/. Accessed 14 May 2013
van der Linden M, von Kries R, Imöhl M (2012) Effects of three years of immunization with higher valent pneumococcal conjugate vaccines on serotype distributions among reported IPD cases in German children and adults. Presented at the 52nd ICAAC, September 9–12, 2012, San Francisco, CA, USA. Available online at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=becf1b8c-545a-4792-ac02-4a9cb31fdf7b&cKey=bb809851-e003-4b87-8957-043e6ed60add&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d. Accessed 12 August 2014
Félix S, Valente C, Tavares DA, Nunes S, Brito-Avô A, de Lencastre H, Sá-Leão R (2012) Temporal trends of serotypes included in the novel 13-valent pneumococcal conjugate vaccine (PCV13) among young children from Portugal. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil, March 11–15, 2012. Available online at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf. Accessed 12 August 2014
Cohen R, Levy C, Bingen E, Bonnet E, Koskas M, Attal S, Nave I, Fritzell B, Varon E (2011) Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on nasopharyngeal (NP) flora in children with acute otitis media (AOM). Presented at the 51st ICAAC, September 17–20, 2011, Chicago, USA. Available online at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=b0b69d8d-27d1-43f4-8f4e-9b651a2028f3&cKey=a8db6616-5ef8-484f-b65e-4e1d48fcfdac&mKey=0C918954-D607-46A7-8073-44F4B537A439. Accessed 12 August 2014
Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Breiman RF (2000) Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342:681–689
Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF (2013) Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31:6232–6238
Norwegian Institute of Public Health (2013) Vaccination statistics for 2012—95 per cent of 9-year-olds are vaccinated. Norwegian Institute of Public Health. Available online at: http://www.fhi.no/artikler/?id=105667. Accessed 12 August 2014
van der Linden M, Imohl M (2013) Serotype distribution and vaccine coverage among pneumococcal disease in adults in Germany [Poster eP737]. Presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Berlin, Germany, 27–30 April 2013. Available online at: https://www.escmid.org/escmid_library/online_lecture_library/?search=1¤t_page=1&search_term=Linden&entrytype%5B%5D=18&entrytype%5B%5D=20&entrytype%5B%5D=17&entrytype%5B%5D=19&entrytitle%5B%5D=4534. Accessed 12 August 2014
Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, Schuerman L, Kilpi TM (2013) Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 381:214–222
Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL (2013) Have changing pneumococcal vaccination programmes impacted disease in Ontario? Vaccine 31:2680–2685
Afonso ET, Minamisava R, Bierrenbach AL, Escalante JJ, Alencar AP, Domingues CM, Morais-Neto OL, Toscano CM, Andrade AL (2013) Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 19:589–597
van den Bergh MR, Spijkerman J, François N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA (2011) Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 30:e170–e178
Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L (2009) Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 28:S66–S76
Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L (2009) The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J 28:S89–S96
Dicko A, Odusanya OO, Diallo AI, Santara G, Barry A, Dolo A, Diallo A, Kuyinu YA, Kehinde OA, François N, Borys D, Yarzabal JP, Moreira M, Schuerman L (2011) Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial. BMC Public Health 11:882
Ruiz-Palacios GM, Guerrero ML, Hernández-Delgado L, Lavalle-Villalobos A, Casas-Muñoz A, Cervantes-Apolinar Y, Moreira M, Schuerman L (2011) Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants. Hum Vaccine 7:1137–1145
Hammitt LL, Ojal J, Bashraheil M, Morpeth SC, Karani A, Habib A, Borys D, Goldblatt D, Scott JA (2014) Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1–4 years: a randomized controlled trial. PLoS One 9:e85459
Sanofi Pasteur MSD (2014) Pneumovax 23: summary of product characteristics. eMC. Available online at: http://www.medicines.org.uk/emc/medicine/1446. Accessed 12 August 2014
Moberley S, Holden J, Tatham DP, Andrews RM (2013) Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 1:CD000422
World Health Organization (WHO) (2012) Pneumococcal vaccines WHO position paper—2012. Wkly Epidemiol Rec 87:129–144
French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF (2000) 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 355:2106–2111
French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, Mwaiponya M, Zijlstra EE, Molyneux ME, Gilks CF (2010) A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362:812–822
Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 31:3577–3584
Jackson LA, Gurtman A, Rice K, Pauksens K, Greenberg RN, Jones TR, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 31:3585–3593
Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B (2013) Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 31:3594–3602
Schmoele-Thoma A, Jackson LA, Greenberg RN, Frenck R, Gurtman A, Jayawardene D, Emini EA, Gruber W, Scott, DA (2012) The immunogenicity of Prevnar 13 in immunocompetent older adults with stable high risk conditions is comparable to that in healthy older adults. Presented at IDWeek 2012, San Diego, CA, October 17–21, 2012. Available online at: https://idsa.confex.com/idsa/2012/webprogram/Paper36522.html. Accessed 12 August 2014
Frenck R Jr, Thompson A, Senders S, Patterson S, Devlin C, Jansen K, Gruber WC, Emini EA, Scott DA, Gurtman A (2012) 13-valent pneumococcal conjugate vaccine in older children and teens either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil, March 11–15, 2012. Available online at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf. Accessed 12 August 2014
Bundesministerium für Gesundheit (2014) Österreichischer Impfplan 2014. Bundesministerium für Gesundheit. Available online at: http://bmg.gv.at/home/Schwerpunkte/Praevention/Impfen/Oesterreichischer_Impfplan_2014. Accessed 12 August 2014
Conseil Supérieur de la Santé (2013) Vaccination antipneumococcique: vaccination de l’adulte (révision 13). Conseil Supérieur de la Santé. Available online at: http://www.health.belgium.be/filestore/19086989_FR/vaccination%20fiche%20contre%20pneumoccoque.pdf. Accessed 12 August 2014
Statens Serum Institut (2012) Pneumococcal vaccination of persons at increased risk of invasive pneumococcal disease. EPI-NEWS. Available online at: http://www.ssi.dk/English/News/EPI-NEWS/2012/No%2051b%20-%202012.aspx. Accessed 12 August 2014
Terveyden ja hyvinvoinnin laitos (2013) Pneumokokkirokotukset. Rokottajan käsikirja. Available online at: http://www.thl.fi/fi_FI/web/rokottajankasikirja-fi/pneumokokkirokotukset. Accessed 12 August 2014
Haut Conseil de la Santé Publique (2013) Infections invasives à pneumocoque: recommandations vaccinales pour les personnes à risque. Haut Conseil de la Santé Publique. Available online at: http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=355. Accessed 12 August 2014
Richtlinie Schutzimpfungs-Richtlinie Stand (2013) 20. Dezember 2013 des Gemeinsamen Bundesausschusses über Schutzimpfungen nach § 20d Abs. 1 SGB V. Gemeinersamer Bundesausschuss. Available online at: https://www.g-ba.de/downloads/62-492-813/SI-RL_2013-10-01.pdf. Accessed 12 August 2014
Διεύθυνση Δημόσιας Υγιεινής του Υπουργείου Υγείας και Κοινωνικής Αλληλεγγύης. Εθνική Επιτροπή Εμβολιασμών. Πρόγραμμα Εμβολιασμών Ενηλίκων (Αθήνα 21/12/2011, Αρ Πρωτ. Υ1/Γ.Π.οικ.140958) Available: http://static.diavgeia.gov.gr/doc/45%CE%A8%CE%A8%CE%98-2%CE%98%CE%9C. Accessed 12 August 2014
National Immunisation Advisory Committee of the Royal College of Physicians of Ireland (2013) Immunisation Guidelines for Ireland, 2013 Edition (updated June 2014). Chapter 16: pneumococcal infection. Health Service Executive. Available online at: http://www.immunisation.ie/en/HealthcareProfessionals/ImmunisationGuidelines/. Accessed 12 August 2014
Conseil Superieur D’hydiene (2008) Recommandations pour la vaccination contre le pneumocoque par le vaccin 23valent. Grand Duché de Luxembourg. Available online at: http://www.sante.public.lu/fr/recommandations/conseil-maladies-infectieuses/pneumonie/recommandations-vaccinations-2008/pneumonie-recommandations-vaccinatin-pneumocoque-23valent-2008.pdf. Accessed 12 August 2014
Nasjonalt folkehelseinstitutt (2013) Anbefalinger for bruk av pneumokokkvaksine utenfor barnevaksinasjonsprogram i Norge. Nasjonalt folkehelseinstitutt. Available online at: http://www.fhi.no/dokumenter/14a5077fef.pdf. Accessed 12 August 2014
Helse og omsorgsdepartementet (2007) Forskrift om stønad til dekning av utgifter til viktige legemidler mv. (blåreseptforskriften). Lovdata. Available online at: http://www.lovdata.no/for/sf/ho/xo-20070628-0814.html. Accessed 12 August 2014
Socialstyrelsen (1994) SOSFS 1994:26: Socialstyrelsens allmänna råd; Vaccination mot pneumokocker. Socialstyrelsen. Available online at: http://www.socialstyrelsen.se/publikationer1994/1994-10-26. Accessed 12 August 2014
Public Health England (2013) Pneumococcal: the green book, chapter 25. gov.uk. Available online at: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25. Accessed 12 August 2014
Obenga G, Mahlaoul N, Launay O (2009) Recommandations vaccinales chez les patients atteints de déficit immunitaire héréditaire. CEREDIH. Available online at: http://www.ceredih.fr/documents/Recos_Vaccins_20091113.pdf. Accessed 12 August 2014
Dominguez V, Arrazola P, Campins M, Chamorro J, de Diego J, Fenoli A, Gil A, Mollar J, Quintas C, Torres Lana A (2012) Recomendaciones de vacunación antineumocócica en el adulto por indicación médica. SEMPSPH. Available online at: http://www.sempsph.com/images/stories/recursos/pdf/protocolos/2012/Recom_Vac_Antineumococica_SEMPSPH.pdf. Accessed 12 August 2014
Jiménez R, Solano R, Riesco M, Altet G, Signes-Costa M, Lorza B, de Granda O, Ramos P, de Higes M, Plaza V, Celdrán G, Martínez M, Santacruz S (2012) Recomendaciones para la vacunación neumocócica en fumadores. Prev Tab. Available online at: http://issuu.com/separ/docs/prev_tab_14-4?e=3049452/1121963. Accessed 12 August 2014
Engelhardt M, Eber SW, Germing U, Heimpel H, Kern W, Schmugge M, Haas PS, Minkov M, Theilacker C (2013) Prävention von Infektionen und Thrombosen nach Splenektomie oder funktioneller Asplenie. DGHO Onkopedia. Available online at: http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/praevention-von-infektionen-und-thrombosen-nach/pra-vention-von-infektionen-und-thrombosen-nach.pdf. Accessed 12 August 2014
Robert Koch Institut (2013) Impfungen bei Asplenie (Entfernung der Milz oder Ausfall der Organfunktion). Robert Koch Institut. Available online at: http://www.rki.de/SharedDocs/FAQ/Impfen/AllgFr_ImpfGesundheitsschaden/FAQ01.html?nn=2391120. Accessed 12 August 2014
Società scientifiche dell’Igiene pubblica, Federazione Italiana Medici Pediatri, and Federazione Italiana Medici di Medicina Generale (2012) Calendario Vaccinale per la Vita. Società scientifiche dell’Igiene pubblica. Available online at: http://www.societaitalianaigiene.org/site/new/images/docs/calendariovaccinale/2012/cvplv.pdf. Accessed 12 August 2014
World Health Organization (WHO) (2005) Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. WHO. Available online at: http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.18.pdf Accessed 12 August 2014
Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P (2013) Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother 9:699–706
Kuhlmann A, Theidel U, Pletz MW, von der Schulenburg JM (2012) Potential cost-effectiveness and benefit–cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev 2:4
Hak E, Grobbee DE, Sanders EA, Verheij TJ, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, Patterson S, van Alphen AJ, Bonten MJ (2008) Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 66:378–383
clinicaltrials.gov (2014) Study Evaluating the Efficacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults (CAPITA). clinicaltrials.gov. Available online at: http://www.clinicaltrials.gov/ct2/show/NCT00744263?term=Prevenar+13&rank=92. Accessed 12 August 2014
Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E (2013) The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 30:127–151
Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, Sprenger R, Bonnet E (2012) The impact of 7-valent pneumococcal conjugate vaccine (PCV7) on pneumonia and mortality: a literature review. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil, March 11–15, 2012. Available online at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf. Accessed 12 August 2014
Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, Scherzinger K, MacInnes K, Beall B, Whitney C (2012) Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S., 2010–11. Presented at IDWeek 2012, San Diego, CA, October 17–21, 2012. Available online at: https://idsa.confex.com/idsa/2012/webprogram/Paper36569.html. Accessed 12 August 2014
Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C (2012) First impact data of 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease in children in Madrid, 2010–2011 (Heracles study). Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil, March 11–15, 2012. Available online at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf. Accessed 12 August 2014
Georgakopoulou T, Menegas D, Tzanakaki G, Pipa E, Vernardaki A, Mavraganis P, Theodoridou M., Kremastinou J (2012) Epidemiology of bacterial meningitis in Greece, in the era of conjugate vaccines: a 7 years review 2005–2011. Presented at the 52nd ICAAC, San Francisco, CA, USA, September 9–12 2012. Available online at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d201a978-86b7-4126-b4eb-dce82709451f&cKey=fd9b920f-2dad-4c23-9dba-3f0f20b33da8&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d. Accessed 12 August 2014
Pardo-Sanchez F, García-Magan C, Martinon-Torres N, Guinda Gimenez M, Méndez-Lage S, Seoane-Pilado MT, Pertega-Diaz S, Martinon-Torres F (2012) Early impact of a universal immunization program with the 13-valent conjugate pneumococcal vaccine in Santiago de Compostela area (Spain). Abstract 588. Presented at the 30th Annual Meeting of the European Society for Paediatric Infectious Diseases, Thessaloniki, Greece, May 8–12 2012. Available online at: http://espid.kenes.com/Documents/ESPID2012%20ABSTRACTS.pdf. Accessed 12 August 2014
Pichichero M, Casey JR, Center K, Chen L, Mathur P, Durham K, Gurtman A, Scott DA (2012) Efficacy of PCV13 in prevention of AOM and NP colonization in children: first year of data from the US. Presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil, March 11–15, 2012. Available online at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf. Accessed 12 August 2014

Similar publications